Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Immunotherapy
• Oncology

Background:

• Hepatocellular carcinoma (HCC) is a prevalent global cancer with limited therapeutic options.
• Alpha-fetoprotein (AFP) is a key oncofetal antigen and diagnostic marker for HCC.
• While AFP is a target for HCC immunotherapy, its weak immunogenicity and immune escape mechanisms pose challenges.

Purpose of the Study:

• To explore strategies for enhancing the immunogenicity of alpha-fetoprotein (AFP) for liver cancer immunotherapy.
• To evaluate the potential of modified AFP-based vaccines in eliciting antitumor immunity.

Main Methods:

• In vitro modification of AFP to enhance its immunogenicity.
• Development and evaluation of AFP-modified immune cell vaccines and peptide vaccines.

Main Results:

• Modified AFP demonstrated enhanced immunogenicity and immune response.
• AFP-modified vaccines induced specific antitumor immunity against AFP-positive tumor cells.
• The approach showed potential in overcoming AFP-related immune escape.

Conclusions:

• In vitro modification can significantly enhance AFP immunogenicity for liver cancer immunotherapy.
• AFP-modified vaccines represent a promising strategy for treating AFP-positive hepatocellular carcinoma.
• This approach lays a foundation for improved liver cancer immunotherapy.